Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
(Thomson Reuters ONE) -
Novartis International AG /
Important new analysis shows that Novartis' Entresto® is associated with higher
relative health-related quality of life scores among HFrEF patients
. Processed and transmitted by Nasdaq Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
* New analysis of PARADIGM-HF data shows that among patients who had been
hospitalized for heart failure, those on Entresto reported higher relative
health-related quality of life (HRQL) scores compared to those taking ACE
inhibitor enalapril[1]
* In the overall study population, declines in HRQL scores were associated
with an increased risk of worse outcomes, including CV death or heart
failure hospitalization, a second analysis reported[2]
* Findings further support clinical benefits of Entresto and reinforce the
urgency to treat appropriate patients with reduced ejection fraction (HFrEF)
Basel, September 19, 2016 - A new post-hoc analysis demonstrates that the
decline in health-related quality of life (HRQL) scores associated with a heart
failure (HF) hospitalization among patients taking Novartis' Entresto(®)
(sacubitril/valsartan) was lower - approximately 50% less of a decline -
compared to those taking ACE inhibitor enalapril[1]. A second post-hoc analysis
in the overall study population shows an association between decline in HRQL
score and increased risk of cardiovascular (CV) death and HF hospitalization[2].
The findings are based on data from PARADIGM-HF, the largest clinical trial ever
conducted in HF[3], and are being presented at the Heart Failure Society of
America (HFSA)'s 20(th) Annual Scientific Meeting in Orlando.
"Heart failure hospitalizations can significantly decrease a patient's quality
of life and lead to poorer outcomes," said Eldrin F. Lewis, MD, MPH, Associate
Physician at Brigham and Women's Hospital and Associate Professor of Medicine,
Harvard Medical School. "Heart failure management must focus on strategies to
reduce this decline by better managing symptoms which can lead to
hospitalization. These analyses suggest that sacubitril-valsartan may help
mitigate the impact of heart failure hospitalization on a patient's health-
related quality of life, and make a strong case for it as part of optimal
treatment of heart failure with reduced ejection fraction."
Regardless of treatment, patients experienced a decrease in HRQL following a HF
hospitalization[1]. The first analysis demonstrated that the decline in HRQL
associated with a HF hospitalization among Entresto patients was significantly
less compared to that of patients taking enalapril[1].
* 6,981 patients in PARADIGM-HF completed a Kansas City Cardiomyopathy
Questionnaire (KCCQ) to measure HRQL at baseline and at eight months of
treatment; during those eight months, 305 patients were hospitalized for
HF[1].
* Among patients who had been hospitalized for HF, those on Entresto
experienced lower declines in HRQL (approximately half) compared to those on
enalapril (5.11 point decline vs. 10.77 point decline in KCCQ Clinical
Summary Score (KCCQ-CSS) for Entresto and enalapril, respectively;
p=0.003)[1].
Patients in the PARADIGM-HF study completed a KCCQ at randomization, four
months, eight months and annually[1]. KCCQ is a self-administered HRQL measure
for HF patients, and the clinical summary score of the KCCQ uses a scale from 0
to 100, with higher scores indicating fewer symptoms and physical limitations
associated with HF[4]. In the overall patient population of PARADIGM-HF, at
eight months of treatment, HRQL, as measured by the KCCQ clinical summary score,
declined less in patients treated with Entresto than those patients treated with
enalapril (2.99 point decline vs. 4.63 point decline for Entresto and enalapril,
respectively; least squares mean of the between-group difference 1.64; 95% CI
0.63-2.65; p=0.001)[4].
A second post-hoc analysis examined the association between HRQL and patient
outcomes in the overall patient population, and found that clinically meaningful
worsening in HRQL scores (defined as a >= 5 point decrease in the KCCQ clinical
summary score) after four months of treatment was associated with an increased
risk of worse clinical outcomes, including CV death or HF hospitalization[2].
* 7,155 patients completed a KCCQ at baseline and at four months of
treatment[2].
* Patients with a decline in HRQL, defined by a decrease of at least five
points in the KCCQ clinical summary score at four months, were subsequently
at a 24% higher risk of CV death (p=0.009) or 28% higher risk of HF
hospitalization (p=0.004)[2].
"We have already seen from PARADIGM-HF that Entresto significantly reduces the
risk of cardiovascular death and heart failure hospitalization in heart failure
patients with reduced ejection fraction." said Vasant Narasimhan, Global Head,
Drug Development and Chief Medical Officer, Novartis. "This new analysis of the
data demonstrates that Entresto can also help reduce the serious impact on
quality of life associated with heart failure, and further reinforces the
potential of this medicine to improve the outlook for patients living with this
debilitating condition."
About Heart Failure
Heart failure is a debilitating and life-threatening condition, which impacts
over 60 million people worldwide[5]. It is the leading cause of hospitalization
in people over the age of 65[6],[7]. About half of people with heart failure
have HFrEF[8]. Reduced ejection fraction means the heart does not contract with
enough force, so less blood is pumped out[9]. Heart failure presents a major and
growing health-economic burden that currently costs the world economy $108
billion every year[6],[10], which accounts for both direct and indirect costs.
Novartis has established the largest global clinical program in the heart
failure disease area across the pharma industry to date, FortiHFy, comprising
over 40 active or planned clinical studies designed to generate an array of
additional data on symptom reduction, efficacy, quality of life benefits and
real world evidence with Entresto, as well as to extend understanding of heart
failure.
About Entresto
Entresto is a twice-a-day medicine that reduces the strain on the failing heart.
It does this by enhancing the protective neurohormonal systems of the heart (NP
system) while simultaneously suppressing the harmful effects of the overactive
renin-angiotensin-aldosterone system (RAAS)[11],[12]. Other heart failure
medicines only block the harmful effects of the overactive RAAS[13]. Entresto
contains the neprilysin inhibitor sacubitril and the angiotensin receptor
blocker (ARB) valsartan[11].
In Europe, Entresto is indicated in adult patients for treatment of symptomatic
chronic heart failure with reduced ejection fraction. In the US Entresto is
indicated for the treatment of heart failure (NYHA class II-IV) in patients with
systolic dysfunction[11]. It has been shown to reduce the rate of cardiovascular
death and heart failure hospitalization compared to enalapril, and also to
reduce the rate of all-cause mortality compared to enalapril. Entresto is
usually administered in conjunction with other heart failure therapies, in place
of an ACE inhibitor or other angiotensin receptor blocker (ARB). Approved
indications may vary depending upon the individual country.
Disclaimer
The foregoing release contains forward-looking statements that can be identified
by words such as "support," "being presented," "can," "lead to," "strategies,"
"suggest," "may," "make a strong case," "potential," "outlook," "growing,"
"planned," or similar terms, or by express or implied discussions regarding
potential new indications or labeling for Entresto, or regarding potential
future revenues from Entresto. You should not place undue reliance on these
statements. Such forward-looking statements are based on the current beliefs and
expectations of management regarding future events, and are subject to
significant known and unknown risks and uncertainties. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those set forth in the
forward-looking statements. There can be no guarantee that Entresto will be
submitted or approved for any additional indications or labeling in any market,
or at any particular time. Nor can there be any guarantee that Entresto will be
commercially successful in the future. In particular, management's expectations
regarding Entresto could be affected by, among other things, the uncertainties
inherent in research and development, including unexpected clinical trial
results and additional analysis of existing clinical data; unexpected regulatory
actions or delays or government regulation generally; the company's ability to
obtain or maintain proprietary intellectual property protection; general
economic and industry conditions; global trends toward health care cost
containment, including ongoing pricing pressures; unexpected safety, quality or
manufacturing issues, and other risks and factors referred to in Novartis AG's
current Form 20-F on file with the US Securities and Exchange Commission.
Novartis is providing the information in this press release as of this date and
does not undertake any obligation to update any forward-looking statements
contained in this press release as a result of new information, future events or
otherwise.
About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland, Novartis
offers a diversified portfolio to best meet these needs: innovative medicines,
eye care and cost-saving generic pharmaceuticals. Novartis is the only global
company with leading positions in these areas. In 2015, the Group achieved net
sales of USD 49.4 billion, while R&D throughout the Group amounted to
approximately USD 8.9 billion (USD 8.7 billion excluding impairment and
amortization charges). Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are available in more than
180 countries around the world. For more information, please visit
http://www.novartis.com.
Novartis is on Twitter. Sign up to follow (at)Novartis at
http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-
library
For questions about the site or required registration, please contact
media.relations(at)novartis.com
References
[1] Lewis EF, Claggett B, McMurray JJ, et al. Sacubitril/Valsartan Associated
with Lower Declines in Health-Related Quality of Life Compared with Enalapril in
Patients with Heart Failure Hospitalization. J Card Fail (2016), doi:
http://dx.doi.org/10.1016/j.cardfail.2016.06.080.
[2] Lewis EF, Claggett B, McMurray JJ, et al. Association between Baseline, and
Changes in, Health-Related Quality of Life and Death and HF Hospitalization in
PARADIGM-HF. J Card Fail (2016), doi:
http://dx.doi.org/10.1016/j.cardfail.2016.06.293.
[3] McMurray JJ, Packer M, Desai AS, Gong J, et al. Baseline characteristics and
treatment of patients in Prospective comparison of ARNI with ACEI to Determine
Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).
Eur J Heart Fail. 2014;16:817-825 (doi:10.1002/ejhf.1s15).
[4] McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition
versus Enalapril in Heart Failure. N Engl J Med. 2014;371:993-1004. doi:
10.1056/NEJMoa1409077.
[5] Global Burden of Disease Study 2013 Collaborators. Global, regional, and
national incidence, prevalence, and years lived with disability for 301 acute
and chronic diseases and injuries in 188 countries, 1990-2013: a systematic
analysis for the Global Burden of Disease Study 2013, Lancet 2015
[6] Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke
Statistics-2016 Update: A report from the American Heart Association.
Circulation. 2015;133;e38-e360. doi: 10.1161/CIR.0000000000000350.
[7] Weir LM, Pfuntner A, Maeda J, et al. HCUP facts and figures: statistics on
hospital-based care in the United States, 2009. Rockville, MD: Agency for
Healthcare Research and Quality, 2011.
[8] Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of
heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259.
[9] Ejection Fraction Heart Failure Measurement. American Heart Association
Website.http://www.heart.org/HEARTORG/Conditions/HeartFailure/SymptomsDiagnosiso
fHeartFailure/Ejection-Fraction-Heart-Failure-
Measurement_UCM_306339_Article.jsp. Published March 24, 2015. Accessed March
10, 2016.
[10] Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart
failure in the United States: a policy statement from the American Heart
Association. Circ Heart Fail. 2013;6:606-619.
[11] Entresto Prescribing Information
[12] Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with
LCZ696: a novel approach for the treatment of heart failure. Drug Discovery
Today. 2012:4: e131-9.
[13] Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the
management of heart failure: A report of the American College of Cardiology
Foundation/American Heart Association task force on practice guidelines.
Circulation. 2013;128:e240-e327.
# # #
Novartis Media Relations
Central media line: +41 61 324 2200
E-mail: media.relations(at)novartis.com
Eric Althoff Elizabeth Ford
Novartis Media Relations Novartis Pharma Communications
+41 61 324 7999 (direct) +41 61 324 4976 (direct)
+41 79 593 4202 (mobile) +41 79 546 11 75 (mobile)
eric.althoff(at)novartis.com Elizabeth.Ford(at)novartis.com
Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations(at)novartis.com
Central North America
Samir Shah +41 61 324 7944 Richard Pulik +1 212 830 2448
Pierre-Michel Bringer +41 61 324 1065 Sloan Pavsner +1 212 830 2417
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188
Media Release (PDF):
http://hugin.info/134323/R/2042924/762614.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 19.09.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 495410
Anzahl Zeichen: 16266
contact information:
Town:
Basel
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 240 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients"
steht unter der journalistisch-redaktionellen Verantwortung von
Novartis International AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
